Federated Hermes
STOK icon

Federated Hermes’s Stoke Therapeutics STOK Stock Holding History

Federated Hermes’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,076
Closed -$4.24K – 2197
2023
Q3 		$4.24K Buy
+1,076
New +$7.08K ﹤0.01% 1904
2022
Q3 		– Sell
-249,364
Closed -$3.29M – 2241
2022
Q2 		$3.29M Buy
249,364
+181,014
+265% +$2.75M 0.01% 798
2022
Q1 		$1.44M Sell
68,350
-666,485
-91% -$13.3M ﹤0.01% 1121
2021
Q4 		$17.6M Sell
734,835
-47
-0% -$1.12K 0.03% 520
2021
Q3 		$18.7M Sell
734,882
-116,993
-14% -$3.26M 0.04% 485
2021
Q2 		$28.7M Sell
851,875
-20,389
-2% -$721K 0.05% 398
2021
Q1 		$33.9M Sell
872,264
-96,547
-10% -$5.5M 0.07% 367
2020
Q4 		$60M Buy
968,811
+138,411
+17% +$6.35M 0.12% 211
2020
Q3 		$27.8M Hold
830,400
– – 0.07% 344
2020
Q2 		$19.8M Hold
830,400
– – 0.05% 397
2020
Q1 		$19M Buy
830,400
+56,983
+7% +$1.41M 0.06% 342
2019
Q4 		$21.9M Buy
773,417
+197,417
+34% +$4.97M 0.05% 393
2019
Q3 		$12.4M Buy
576,000
+461,000
+401% +$12.9M 0.03% 500
2019
Q2 		$3.35M Buy
+115,000
New +$3.09M 0.01% 911

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes's STOK Position: Q4 2023 in Review

Federated Hermes sold out of Stoke Therapeutics (STOK) in Q4 2023, closing a stake of 1,076 shares — an estimated $4.24K sold.

Federated Hermes first reported a position in STOK in Q2 2019 and held it in 14 quarters. The position peaked at $60M in Q4 2020. 81 funds tracked by Wall St. Rank hold STOK as of Q4 2023.

  • Federated Hermes reported no remaining Stoke Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Federated Hermes sold 1,076 Stoke Therapeutics shares in Q4 2023, an estimated $4.24K.
  • Federated Hermes first reported a position in Stoke Therapeutics in Q2 2019 and held it in 14 quarters.
  • Federated Hermes's Stoke Therapeutics position peaked at $60M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2023.

Based on Federated Hermes's 13F filing for Q4 2023, filed 31 Jan 2024.